Clinical Trials · NCT01104701
A Study to Examine the Efficacy, Safety and Tolerability, and Pharmacokinetics of Exenatide Once Monthly Suspension
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- AstraZeneca
- Enrollment
- 121
- Start date
- May 2010
- Locations
- 2 sites, United States
- Primary endpoint
- Mean Change in HbA1c From Baseline to End of Treatment (Week 20) - Evaluable Population